ArgoMD

Longevity focused telehealth platform

[ArgoMD @ArgoMD_Health]

@grok @TXSheikh @HealthyAlfred How was this administered to the rats? @grok

[ArgoMD @ArgoMD_Health]

7/ If you're on a GLP-1 and not thinking about lean mass, you're playing half the game.

Bring it up with a licensed provider.

Start an intake at https://t.co/WRdWblRfQY and see if this is right for you.

[ArgoMD @ArgoMD_Health]

1/ You lost 40 lbs on a GLP-1. Genuinely congrats.

But trial analyses suggest a meaningful share of weight lost, often cited around a quarter or more, can be lean mass. Not fat.

Here's the part of the conversation that actually matters. 🧵

[ArgoMD @ArgoMD_Health]

6/ So the honest state of play:

GLP-1s are proven metabolic medicines. The lean-mass question is real. And today's answer is training, protein, and a provider who tracks body composition.

Not a mystery add-on.

[ArgoMD @ArgoMD_Health]

5/ Growth-hormone biology often enters this conversation, and that is exactly where FDA labels matter.

Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for GLP-1 muscle preservation.

Sermorelin is compounded-only and not currently FDA-approved.

[ArgoMD @ArgoMD_Health]

4/ The evidence-based playbook is boring and true:

Resistance training. Adequate protein. And a provider watching how your body composition changes, not just the number on the scale.

[ArgoMD @ArgoMD_Health]

3/ Why does that matter?

Lean mass matters for strength, function, and resting energy use.

Losing weight is the goal. Losing capability is not.

[ArgoMD @ArgoMD_Health]

2/ First: this is not a GLP-1 problem.

Any significant weight loss, from any method, can pull from lean tissue along with fat. These medicines just made it happen faster, for more people, than anything before them.

[ArgoMD @ArgoMD_Health]

@MartinShkreli Insulin is a peptide. It won a Nobel Prize in 1923.

The last time you were this confident about a position, the DOJ auctioned your Wu-Tang album.

Short away, Martin.

We are going long on peptides to support human longevity.

[Polymarket @Polymarket]

JUST IN: FDA advisory panel votes to expand pharmacy access to BPC-157, a peptide promoted for injury recovery and gut healing.

[Jesse Morse, M.D. @DrJesseMorse]

Here’s a MASSIVE summary of Retatrutide - the upcoming triple agonist from Eli Lilly and how it compares to Tirzepatide and Semaglutide.

What about side-by-side side effect comparison by dose?
What do the trials show?

Full detailed article in attached tweet below.

[Dr Danish @operationdanish]

🤯 JUST IN: INCREDIBLE PHASE 3 DATA ON RETATRUTIDE PRESENTED AT ADA

At ADA this weekend, Eli Lilly ($LLY ) presented new Phase 3 data from TRIUMPH-1 and TRANSCEND-T2D-1. BLUF: 28% (70 pounds) weight loss. Unreal.

In TRIUMPH-1, participants receiving 12 mg of retatrutide lost an average of 70.3 pounds (28.3%) over 80 weeks. Nearly half achieved at least 30% weight loss, and 65.3% were no longer classified as obese (BMI <30) by the end of the study. Among participants who started with BMI ≥35 and continued treatment to 104 weeks, average weight loss reached 85 pounds (30.3%), with no evidence that weight loss had fully plateaued.

What stood out more was the breadth of effect across obesity-related conditions:

Knee osteoarthritis pain improved by 73.1%
Obstructive sleep apnea severity improved by 60.6%
Triglycerides fell by as much as 41.0%
Non-HDL cholesterol declined by 24.2%
Systolic blood pressure dropped by 12.3 mmHg
Waist circumference decreased by 9.5 inches

Meanwhile, in TRANSCEND-T2D-1, retatrutide produced A1C reductions of up to 2.0% from a baseline of 7.9%.

90% of patients achieved A1C <7%
85% achieved A1C ≤6.5%
46% reached A1C <5.7%, which is below the threshold used to define prediabetes
Patients lost 36.6 pounds (16.8%) at 40 weeks, and weight loss was still ongoing at study end.

Obesity medicine is increasingly becoming outcomes medicine.

Historically, we have evaluated obesity drugs primarily on percent weight loss... but payers ultimately care about sleep apnea, osteoarthritis, diabetes, cardiovascular risk, and healthcare costs.

The significance of TRIUMPH-1 and TRANSCEND-T2D-1 is that Lilly is beginning to show a coherent story across those endpoints, not just body weight. I expect this to expand coverage dramatically.

Eli Lilly is the Nvidia of healthcare.

[Afshine Emrani MD FACC @afshineemrani]

1/5
I'm a cardiologist. Here's why I recommend men take 5 mg of tadalafil — Cialis — every single day.
Not for ED. Not for performance.
I take it for the same reason every serious longevity physician I respect does: to protect my cardiovascular system, my brain perfusion, and my endothelial health at the most fundamental level.
This drug — famous for all the wrong reasons — has quietly become one of the most powerful tools in preventive cardiology. And the data is now too strong for me to keep quiet about it.

[Afshine Emrani MD FACC @afshineemrani]

1/5
I'm a cardiologist. I've been telling you for months that GLP-1 drugs are rewriting medicine far beyond weight loss.
44% less depression. 47% less substance use disorder. 28.7% weight loss. 86% liver fat clearance.
Now add this.
Cleveland Clinic researchers are presenting data at ASCO next week — the biggest cancer conference in the world — showing that GLP-1 medications may cut cancer progression to metastatic disease by up to 50%.
12,112 patients. Seven obesity-related tumor types. Stages 1 through 3.
This class of drugs keeps getting bigger. And the old walls between metabolic medicine, cardiovascular medicine, and oncology keep coming down.